Europe — EMA
Miglustat G.L.
GNH USA supplies Miglustat G.L. (Miglustat), a iminosugar for Gaucher disease type 1 and Niemann-Pick disease type C treatment.
Request sourcing
What is Miglustat?
Miglustat, the active ingredient in Miglustat G.L., is an iminosugar presented as an oral dosage form for oral use. It is indicated for the treatment of Gaucher disease type 1 and Niemann‑Pick disease type C in patients requiring substrate reduction therapy.
GNH USA supplies Miglustat G.L. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Miglustat used for?
Miglustat is used in rare lysosomal storage disorders that involve glycosphingolipid accumulation.
- Gaucher disease type 1: reduces glucosylceramide buildup, helping to improve hematologic parameters and organ size. - Niemann‑Pick disease type C: decreases glycosphingolipid synthesis, supporting neurological function and slowing disease progression.
What are the side effects of Miglustat?
Adverse reactions may vary in frequency and severity.
Common Side Effects: - Diarrhea: loose stools occurring during treatment. - Nausea: feeling of sickness or urge to vomit. - Weight loss: gradual reduction in body weight. - Abdominal pain: discomfort in the stomach area. - Flatulence: increased gas production. - Headache: mild to moderate head pain.
Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas requiring medical attention. - Severe hypersensitivity: rash, swelling, or difficulty breathing. - Elevated liver enzymes: potential liver function abnormalities. - Depression or mood changes: new or worsening psychiatric symptoms. - Seizures: rare occurrence of convulsive episodes.
What precautions apply to Miglustat?
Before initiating therapy, clinicians should consider several safety measures.
- Liver monitoring: assess hepatic function periodically. - Blood glucose: monitor for hypoglycemia, especially in diabetic patients. - Gastrointestinal tolerance: evaluate for persistent diarrhea or nausea. - Psychiatric assessment: watch for signs of depression or mood disorders. - Hypersensitivity: discontinue if severe allergic reactions develop. - Store at below 25°C: keep in the original pack, protect from moisture.
What does Miglustat interact with?
Miglustat may interact with other medicines that affect its metabolism or exacerbate side effects.
Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase miglustat exposure. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce miglustat efficacy.
Moderate Interactions (Monitor Closely): - Antidiabetic agents: increased risk of hypoglycemia. - Warfarin: potential alteration of INR values. - Other gastrointestinal irritants: may worsen GI adverse events.
